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incidence of hematologic toxicity was low (1 G1; 1G2). Early 
response evaluated by instrumental re-staging after 3 months 
from the end of treatment was encouraging, since 8 patients 
achieved complete response and 8 a partial response. Among 
the 6 patients with at least 2 years of follow up, 3 patient 
developed a progression disease (1 local relapse an 2 distant 
metastasis) and 1 patient died of disease after 3 years from 
treatment. The patient who underwent to radiation boost 
after chemoradiation developed anal stenosis which required 
a permanent colostomy. 
 
Conclusion: SIB with VMAT combined with chemotherapy is 
quite feasible in anal cancer treatment. It easily allows 
different dose delivering to target at different risk of disease 
involvement. Split course schedule has not be more used 
because of acceptable acute toxicity profile, which was 
confirmed in conventional fractionation. A larger patient 
number and a longer follow-up are required to confirm our 
data. 
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Purpose or Objective: Radiation treatment for rectal cancer 
is usually given in the prone position on a belly board with 
the aim to move the small bowel away from the treatment 
volume. In practice, this position is sometimes difficult to set 
up reproducibly and is poorly tolerated for some patients. 
With the increasing conformality and accuracy of using VMAT 
and cone beam CT (CBCT), we asked if there was any 
dosimetric advantage of treating rectal patients prone—it 
may be that patients can be better treated in the supine 
orientation. The two aims of this study are 1) to investigate 
setup reproducibility of rectal cancer patients treated in the 
prone and supine positions, and 2) to compare dose-volume 
histogram (DVH) metrics for the bladder and small bowel for 
both treatment positions. 
 
Material and Methods: Eighteen consecutive patients with 
rectal cancer who received neoadjuvant chemoradiation 
were selected for this study. 9 were treated supine and 9 in 
the prone position. Patients were prescribed a total dose of 
50.4 Gy in 1.8 Gy daily fractions according to institutional 
protocol and were planned with a VMAT posterior half arc. To 
determine setup reproducibility, weekly CBCTs were acquired 
and matched to bone. The CBCT-determined translational 
and rotational shifts were recorded. Clinically relevant dose-
volume histogram values were generated for the small bowel 
and bladder.  
 
Results: The CBCT-determined rotational setup error ranges 
for the prone position in pitch, roll, and yaw were [-3.6° 
4.7°], [-4.2° 3.2°], and [-1.4° 1.1°] respectively. For the 
supine position the corresponding ranges were [-4.8° 2.0°], [-
2.4° 1.3°], and [-1.0° 3.2°]. 7 patients exhibited >±3° 
rotational errors in the prone versus only 2 in the supine 
position, indicating better setup reproducibility in the supine 
position. Translational errors were generally <±1 cm in all 
directions for both positions. The small bowel V45 and mean 
dose for prone was 7.3±9.9% and 16.9±6.8 Gy (± values 
represent standard deviations) respectively; for supine the 
values were 6.8±7.6% and 19.6±6.4 Gy. The bladder V30 and 
mean dose for prone were 64.4±14.3% and 36.8±4.1 Gy 
respectively; for supine, these values were 68.7±18.5% and 
37.3±4.1Gy. 
 
Conclusion: There may be increased rotational instability in 
the prone position, but no apparent dosimetric advantage for 
small bowel sparing was observed. Rectal cancer patients 
who undergo neoadjuvant radiation using VMAT and CBCT 
may not need to be treated prone on a belly board. 
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Purpose or Objective: The present study analyses the 
correlation of pre-treatment (18)F-fluorodeoxyglucose 
Positron Emission Tomography/Computed Tomography (FDG-
PET/CT) standardized uptake value (SUV) and total lesion 
glycolysis (TLG) with tumour characteristics and clinical 
response in a series of rectal cancer patients treated with 
neoadjuvant chemo-radiotherapy.  
 
Material and Methods: Fifty-six patients were included in the 
present analysis. Pre-treatment PET maximum SUV (SUVmax), 
mean SUV and TLG of primary tumour were calculated for 
each patient. The total dose of pelvic radiotherapy was 45-
50.4 Gy, 1.8 Gy/fraction. Chemotherapy was delivered with 
capecitabina or 5-fluorouracil. Six to eight weeks after RT-
CT, 44 patients (78.6%) had anterior rectal resection and 12 
patients (21.4%) had abdominal pelvic resection (Miles).  
Tumor Regression Grade (TRG) (Mandard, 1994) was defined 
on surgical specimen. Complete regression (TRG1) was 
observed in 10/56 (17.9 %).The correlation between PET/CT 
results and histopathological data and tumour response was 
analyzed.  
 
Results: At the level of the primary tumour, SUVmax ranged 
from 4.17 and 54.06 (mean 22.46, median 18.96), SUV mean 
ranged from 6.22 and 32.64 (mean 13.42, median 11.09) and 
TLG ranged from 7.96 and 3158.23 (mean 350.21, median 
183.55). 
SUVmax (p=0.05) and TLG (p=0.002) significantly correlated 
with T-stage. Median SUVmax was significantly higher (p = 
0.05) for lesions with partial response (PR, 46/56, 82.1%) 
than for lesions with complete response (CR, 34/54, 17.9%). 
Median TLG was significantly higher (p=0.034) for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%). 
SUVmean was not significantly correlated with T-stage 
(p=0.074). Median SUVmean was higher for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%) but without statistical 
significance (p =0.18).  
 
Conclusion: Our data suggest that pre-treatment FDG-
PET/CT SUVmax and TLG are strongly associated with tumour 
primary tumour stage. Furthermore they correlate with 
prediction of tumour response after neoadjuvant treatment.  
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Purpose or Objective : The present study analyses the 
correlation of pre-treatment (18)F-fluorodeoxyglucose 
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Positron Emission Tomography/Computed Tomography (FDG-
PET/CT) standardized uptake value (SUV) and total lesion 
glycolysis (TLG) with tumour characteristics and clinical 
response in a series of rectal cancer patients treated with 
neoadjuvant chemo-radiotherapy 
 
Material and Methods: Fifty-six patients were included in the 
present analysis. Pre-treatment PET maximum SUV (SUVmax), 
mean SUV and TLG of primary tumour were calculated for 
each patient. The total dose of pelvic radiotherapy was 45-
50.4 Gy, 1.8 Gy/fraction. Chemotherapy was delivered with 
capecitabina or 5-fluorouracil. Six to eight weeks after RT-
CT, 44 patients (78.6%) had anterior rectal resection and 12 
patients (21.4%) had abdominal pelvic resection (Miles).  
Tumor Regression Grade (TRG) (Mandard, 1994) was defined 
on surgical specimen. Complete regression (TRG1) was 
observed in 10/56 (17.9 %).The correlation between PET/CT 
results and histopathological data and tumour response was 
analyzed.  
 
Results: At the level of the primary tumour, SUVmax ranged 
from 4.17 to 54.06 (mean 22.46, median 18.89), SUV mean 
ranged from 6.22 to 32.64 (mean 13.42, median 11.09) and 
TLG ranged from 7.96 to3158.23 (mean 350.21, median 
183.55).SUVmax (p=0.05) and TLG (p=0.002) significantly 
correlated with T-stage. Median SUVmax was significantly 
higher (p = 0.05) for lesions with partial response (PR, 46/56, 
82.1%) than for lesions with complete response (CR, 34/54, 
17.9%). Median TLG was significantly higher (p=0.034) for 
lesions with partial response (PR, 45/54, 83.3%) than for 
lesions with complete response (CR, 9/54, 16.7%). 
SUVmean was not significantly correlated with T-stage 
(p=0.074). Median SUVmean was higher for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%) but without statistical 
significance (p =0.18).  
 
Conclusion: Our data suggest that pre-treatment FDG-
PET/CT SUVmax and TLG are strongly associated with tumour 
primary tumour stage. Furthermore they correlate with 
prediction of tumour response after neoadjuvant treatment 
 
Electronic Poster: Clinical track: Gynaecological 
(endometrium, cervix, vagina, vulva)  
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Purpose or Objective: To evaluate pathological response and 
clinical outcomes in women with locally advanced cervical 
cancer treated with radiochemotherapy and surgery in a 
tertiary hospital. 
 
Material and Methods: In this retrospective analysis we have 
included 59 patients with cervical cancer (FIGO stages IB2-
IVA) who were treated between December 2004 and July 
2015 with concurrent chemoradiation therapy (CCRT) 
followed by surgery. The patients were treated with pelvic 
external beam radiotherapy at 46-50,4 Gy, 1,8-2 Gy/day. 
Based on CT or PET CT if aortic nodes were demonstrated, 
extended external beam radiotherapy was performed. We 
boosted nodes or parametria if they were affected (60-68 Gy, 
2 Gy/day). After four weeks of treatment, patients received 
brachytherapy from 15 to 26 Gy in 3-6 fractions with 2D 
planification or 3D planification (n=28), with a total tumour 
dose between 85 and 90 Gy. Concurrent chemotherapy with 
weekly platin and in some cases oral fluoropirimidine was 
administrated. Overall treatment time did not exceed 8 
weeks. All patients completed surgery between 4-15 weeks 
after CCRT. 
 
Results: The median age was 52 years (range 30 and 77). 
Squamous cell carinoma was the most common subtype 
(81%). All patients received hysterectomy. 7 patients (12%) 
underwent lymphadenectomy. In global, 32 patients (54%) 
had a complete response, 20 (34%) a partial response and 7 
(12 %) patients had residual microscopic disease in the 
pathologic analysis. With a median follow up of 53 months 
(range from 2 to 128 months) overall survival was 85% and 
disease free survival 81% 
 
Conclusion: Our results show that CCRT followed by surgery 
gets excellents outcomes with acceptable toxicity and may 
reduce local recurrences. Besides it enables assessment of 
the pathological response. 
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Purpose or Objective: To quantify the magnitude of clinician 
uncertainty in GTV delineation for patients with recurrent 
gynaecological cancers. 
 
Material and Methods: GTV delineation uncertainty was 
retrospectively investigated in patients previously treated in 
our institution for centrally recurrent gynaecological cancer. 
In order to record clinician delineation uncertainty, clinicians 
were asked to draw 3 outlines per GTV; an inner GTV (GTV_I) 
corresponding to the innermost boundary the GTV is likely to 
have, an outer GTV (GTV_O)corresponding to the outmost 
boundary the GTV is likely to have and a clinical GTV (GTV_C) 
outlined in accordance with local treatment protocols. For 
GTV_C, each observer submitted a confidence score from 1 
to 5, with 1 being no confidence in drawn and 5 complete 
confidence. For each patient, the 3 GTV’s were delineated 
on a co-registered CT-MR, using a local rigid soft tissue 
registration, as well as on MR images only in order to identify 
how the co-registered CT information affects the decision 
process. Paired T Tests (p) were used to test for significance 
and Pearson correlation coefficient (r) for correlations. 
 
Results: To date, 18 recurrences from 17 patients were 
investigated by a single observer. For all 17 MR only contours 
and for 15 out of the 17 CT-MR contours, the GTV_O and 
GTV_C were identical. GTV_C ranged from 6.3 to 192.9cm3 
for CT-MR contours and from 5.5 to 180.1cm3 for the MR only 
contours, with a mean ± standard deviation of 53.3±44.7cm3 
and 39.3±40.4cm3 respectively. The reduction in GTV_I 
relative to GTV_C was 19.6±12.4cm3 (p<0.01) for CT-MR 
contours and 13.3±9.8cm3 (p<0.01) for MR only contours. For 
GTV_C, MR only contours were consistently smaller than CT-
MR contours by 14.0±11.4cm3 (p<0.01). For GTV_I, MR only 
contours were smaller for 13 out of the 17 cases, with 
differences of 7.9±7.7cm3 (p<0.01). The 3D difference in the 
centre of mass (COM) between GTV_O and GTV_C was 2±2mm 
for the CT-MR contours and 2±1mm for the MR only contours. 
Scoring of GTV_C was significantly lower (p<0.01) for CT-MR 
contours relative to MR only contours, with scores of 2.8±0.6 
and 3.6±0.7 respectively. 
 
Conclusion: Uncertainty exists in defining the boundary of 
the GTV for this patient cohort resulting in uncertainty in 
